Treatment with DHMEQ in both in vitro and in vivo models of OSCC have been shown to suppress tumor growth and survival in a dose-dependent manner by inducing DNA fragmentation and downregulating anti-apoptotic proteins such as survivin (126). Here, BIRC5 is linked to neoplasm.